Table 3.
Patients’ chemotherapy for all patients according to programmed cell death ligand-1 (PD-L1).
| n | level | Low PDL-1 | High PD-L1 | P |
|---|---|---|---|---|
| 61 | 43 | |||
| Neoadjuvant chemotherapy regimen (%) | AC/ACF | 3 (4.9) | 1 (2.3) | 0.754 |
| CT/ACT | 7 (11.5) | 3 (7.0) | ||
| AT | 28 (45.9) | 25 (58.1) | ||
| TP | 13 (21.3) | 8 (18.6) | ||
| Others | 10 (16.4) | 6 (14.0) | ||
| Duration of neoadjuvant therapy (%) | <6 | 16 (26.2) | 18 (41.9) | 0.144 |
| ≥6 | 45 (73.8) | 25 (58.1) | ||
| Response (%) | PR | 38 (62.3) | 22 (51.2) | 0.326 |
| SD | 22 (36.1) | 21 (48.8) | ||
| PD | 1 (1.6) | 0 (0.0) | ||
| MPG (%) | 1 | 7 (11.5) | 2 (4.7) | 0.568 |
| 2 | 24 (39.3) | 18 (41.9) | ||
| 3 | 26 (42.6) | 22 (51.2) | ||
| 4 | 1 (1.6) | 0 (0.0) | ||
| 5 | 3 (4.9) | 1 (2.3) | ||
| Postoperative chemotherapy (%) | No | 22 (36.1) | 8 (18.6) | 0.086 |
| Yes | 39 (63.9) | 35 (81.4) | ||
| Postoperative chemotherapy regimen (%) | AC/ACF | 7 (11.5) | 2 (4.7) | 0.068 |
| CT/ACT | 1 (1.6) | 5 (11.6) | ||
| AT | 6 (9.8) | 3 (7.0) | ||
| TP | 9 (14.8) | 8 (18.6) | ||
| Others | 16 (26.2) | 17 (39.5) | ||
| NO | 22 (36.1) | 8 (18.6) | ||
| Postoperative chemotherapy times (%) | <4 | 36 (59.0) | 12 (27.9) | 0.003 |
| ≥4 | 25 (41.0) | 31 (72.1) |
A, Anthracyclines; C, Cyclophosphamide; F, 5-Fluorouracil; T, Taxol; P, Platinum compounds.